# Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct02089126` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02089126](<https://clinicaltrials.gov/study/NCT02089126>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02089126

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 230 participants.

## Technical summary

Registry record NCT02089126. Randomized; triple masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2016-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 230 participants (planned count; ClinicalTrials.gov record NCT02089126, source copy `cardio:ctgov-nct02089126-2014-03-17`, retrieved 2026-10-26)
- Start date: 2014-06 (registry gives no type) (ClinicalTrials.gov record NCT02089126, source copy `cardio:ctgov-nct02089126-2014-03-17`, retrieved 2026-10-26)
- Primary completion: 2016-09 (anticipated) (ClinicalTrials.gov record NCT02089126, source copy `cardio:ctgov-nct02089126-2014-03-17`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: South Korea (ClinicalTrials.gov record NCT02089126, source copy `cardio:ctgov-nct02089126-2014-03-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02089126-2014-03-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Gemigliptin/Glimepiride combination
- Lead sponsor: LG Life Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: LG Life Sciences (`cardio:org-lg-life-sciences`)

## Provenance

Content hash: 567c8065a9ae1aa9acdc5d697bfedb08ede95a25c33c35659c0ff322e0223d07
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
